A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Trial Profile

A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Technetium tc 99m trofolastat (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Diagnostic use
  • Sponsors Molecular Insight Pharmaceuticals
  • Most Recent Events

    • 24 Mar 2017 According to a Progenics Pharmaceuticals media release, results from this study were published online in the Journal of Nuclear Medicine.
    • 12 Oct 2015 Results presented at the 28th Annual European Association of Nuclear Medicine (EANM) Congress, according to a Progenics Pharmaceuticals media release.
    • 22 Oct 2014 Results presented at the 27th Annual Congress of the European Association of Nuclear Medicine, according to a Progenics Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top